The 'fair and reasonable' price mandated for new coronavirus vaccines and therapeutics under new US legislation may wind up a largely subjective decision for the government officials that would be tasked with any procurement.
With little data and no competitors as a benchmark, the sponsor’s accounting of costs plus a mark-up for profit may...







